defactinib,
N-methyl-4-((4-(((3-methyl(methylsulfonyl)aminopyrazin-2-yl)methyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzamide,
PF-04554878,
VS-6063,
Defactinib,
1073154-85-4,
VS-6063,
PF-04554878,
UNII-53O87HA2QU,
Defactinib (VS-6063, PF-04554878),
53O87HA2QU,
1345713-71-4,
N-methyl-4-((4-(((3-(N-methylmethylsulfonamido)pyrazin-2-yl)methyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzamide,
Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-,
Defactinib [USAN:INN],
N-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamide,
Defactinib (USAN/INN),
PF-4554878,
GTPL7910,
SCHEMBL1627234,
C20H21F3N8O3S,
CHEMBL3137331,
Defactinib (PF-04554878),
AOB87723,
BCP11299,
EX-A1037,
EX-A1049,
2361AH,
MFCD25977806,
s7654,
AKOS026750300,
ZINC103297739,
CS-3410,
DB12282,
SB17060,
VS 6063,
NCGC00386425-06,
NCGC00386425-11,
AK546976,
AS-17045,
BC600623,
DA-45890,
HY-12289,
FT-0706351,
FT-0721609,
Defactinib (VS-6063 PF-04554878),
J3.502.756D,
PF 04554878,
A11929,
D10618,
J-690021,
7KD,
N-Methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)pyrazin-2-yl)methyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzamide,
N-methyl-4-(4-((3-(N-methylmethylsulfonamido)pyrazin-2-yl)methylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)benzamide,
Glasdegib,
D0V6EV,
D0Y1UO,
Defactinib?PF-04554878?,
FAK inhibitors (cancer), Pfizer,
PF-941222,
B4800,
~{N}-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamide,
1073160-26-5,
Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino],